Global Cannabinoid Solutions launches fully bespoke clinical cannabinoid training — impartial cannabinoids curricula built around any disease area, condition or drug

A new commissioned-curriculum service lets hospitals, clinics and healthcare organisations own independent, evidence-led cannabinoid education — branded to them, and theirs to keep.

MIDDLESBROUGH, UK — 13 JULY 2026. Global Cannabinoid Solutions (GCS) today announced the launch of its Bespoke Clinical Curriculum service, an extension of its clinical training suite for medical cannabis prescribers, doctors and pharmacists. Where most professional cannabis education is generic — and increasingly produced by the very companies that manufacture the products — GCS builds independent training to order, shaped entirely around each organisation's clinical priorities.

The service covers any disease area, any condition, and any drug. A hospital oncology unit, a neurology clinic, a pain service or a mental-health team can each commission modules tailored to the patients they treat, the formulations they use and the questions their clinicians actually face — from common presentations to rare and complex cases.

Crucially, the curriculum belongs to the organisation. Each programme carries the client's own brand and identity, can be delivered internally to their teams, and remains theirs to keep — refreshed by GCS as the evidence base evolves.

"When the company selling the product also writes the syllabus, impartiality is the first thing to go. Clinicians deserve education built around their patients — not around anyone's product line. That's what a bespoke, independent curriculum delivers."

— Christopher Tasker, Founder & CEO, Global Cannabinoid Solutions

Rigour of GCS, focus of the client

Every bespoke programme is grounded in the same rigour as the core GCS suite — real prescribing insight, cannabinoid pharmacology and unbiased evidence appraisal, shaped around the cases each team actually sees. Clinicians can apply their learning toward their ongoing CPD requirements, and programmes flex to how each organisation works: self-paced, guided sessions or workshops.

GCS receives no manufacturer funding, and its education carries no product bias — a position the company argues is essential as medical cannabis moves further into mainstream clinical practice.

Availability

The Bespoke Clinical Curriculum service is available now to healthcare organisations worldwide. Organisations can scope a programme at cannabissciencetraining.com.

What it does for your team

Built around outcomes, not checklists

A bespoke curriculum is designed to move a whole team forward — measured by what clinicians can do differently afterwards, and what that means for the organisation and its patients.

• CONFIDENCE - Prescribe with certainty. Move clinicians from guesswork to clear, evidence-based decisions.

• ONBOARDING - Get new starters up to speed. Bring every new engagement to a shared baseline, fast.

• SAFER CARE - Reduce clinical risk. Close knowledge gaps and cut avoidable errors.

• CPD - Meet CPD requirements. Structured learning your team can apply toward ongoing CPD.

• CAPABILITY - Raise the whole team. One standard, beginner to advanced — a more capable clinician at every level.

• PATIENT TRUST - Answer the hard questions. Clinicians who can explain the science, not just the script.

Bespoke by design: every programme is built around any disease area, condition or drug the team needs — branded to the organisation and theirs to keep.

About Global Cannabinoid Solutions

Global Cannabinoid Solutions is an independent cannabinoid science and education company. Through its clinical training suite and digital cannabinoid laboratory, GCS gives prescribers, healthcare organisations and industry access to impartial, evidence-led expertise across the endocannabinoid system — helping them prescribe, build and decide with certainty.

Media contact

Global Cannabinoid Solutions
Christopher Tasker, Founder & CEO
chris@globalcannabinoidsolutions.com
cannabissciencetraining.com